Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
China channel feed
Foreign investors fled Chinese biotech after the pandemic. They still haven’t come back
Last year
Financing
US-China tensions threaten to ensnare additional Chinese biopharma contractors
Last year
Pharma
Manufacturing
WuXi builds out lobbying bench amid legislative effort to blacklist company
Last year
Pharma
FDA+
Three more I-Mab execs exit after US/China operations split
Last year
People
Congress' China hawks seek to add biotech suppliers to Pentagon warning list
Last year
FDA+
Updated: US intelligence officials told Congress that WuXi transferred IP to Chinese authorities — report
Last year
Pharma
WuXi AppTec, WuXi Biologics continue to build out US presence despite political tensions
Last year
Manufacturing
Hunting for ‘certainty and stability,’ WuXi Bio spotlights client relationships
Last year
Manufacturing
The US could upend biopharma manufacturing. WuXi rivals have an opening
Last year
In Focus
Manufacturing
Nuvation inks all-stock deal for US-China oncology biotech AnHeart
Last year
Startups
Deals
Lead House sponsor of WuXi-linked bill to leave Congress early
Last year
People
Pharma
Senate opens probe into how high-risk research poses national security threats
Last year
Pharma
Novo Nordisk bolsters operations in China with $556M expansion project
Last year
Pharma
Manufacturing
WuXi AppTec's 2023 sales largely reliant on the US, report says
Last year
Manufacturing
After years of delay, BeiGene finally lands FDA approval for its PD-1 drug
Last year
Pharma
FDA+
BeiGene looks beyond China as it secures new API source, nears opening of US site
Last year
Manufacturing
BIO to cut ties with WuXi after trade group was accused of acting as a foreign agent
Last year
Pharma
WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down
Last year
Deals
In Focus
Startups raised millions to in-license drugs to China. Then the model fell apart
Last year
Deals
In Focus
Lawmakers call for 'line in the sand' between US and Chinese biotech companies
Last year
Pharma
Law
Senate committee advances bill targeting Chinese manufacturers as BIO faces attack for backing WuXi
Last year
Pharma
Manufacturing
Joining congressional skepticism of China's role in biotech, Biden executive order targets data privacy issues
Last year
Law
Chinese API manufacturer receives FDA warning letter after QC employee says test results 'in my mind'
Last year
FDA+
Manufacturing
Lawmakers’ explosive charges turn a global spotlight on China’s WuXi, and it’s feeling the heat
Last year
Bioregnum
First page
Previous page
5
6
7
8
9
10
11
Next page
Last page